(Q38176745)

English

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

scientific article published on 08 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

5

object named as

Maya Buch

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Cécile Gaujoux-Viala

2

object named as

Cécile Gaujoux-Viala

0 references

Désirée van der Heijde

7

object named as

Désirée van der Heijde

0 references

Robert Landewé

9

object named as

Robert Landewé

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

4

object named as

Josef S Smolen

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

6

object named as

Laure Gossec

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1

object named as

Sofia Ramiro

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

author name string

Cécile Gaujoux-Viala

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Jackie L Nam

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Kevin Winthrop

8

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

8 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

529-535

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

European biologicals registers: methodology, selected results and perspectives

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Evaluation of the quality of prognosis studies in systematic reviews

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Initiation of rheumatoid arthritis treatments and the risk of serious infections

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-α drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Association between anti-TNF-α therapy and all-cause mortality

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

The incidence of gastrointestinal perforations among rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Predictors of infection in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Tofacitinib for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204575

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-204575

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38176745&oldid=2190408166"